Pharmacokinetics and Pharmacodynamics of PARP Inhibitors in Oncology

Olaparib, niraparib, rucaparib, and talazoparib are poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of ovarian, breast, pancreatic, and/or prostate cancer. Poly (ADP-ribose) polymerase inhibitors are potent inhibitors of the PARP enzymes with comparable half-maximal inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruin, Maaike A. C., Sonke, Gabe S., Beijnen, Jos H., Huitema, Alwin D. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734231/
https://www.ncbi.nlm.nih.gov/pubmed/36219340
http://dx.doi.org/10.1007/s40262-022-01167-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9734231/
https://www.ncbi.nlm.nih.gov/pubmed/36219340
http://dx.doi.org/10.1007/s40262-022-01167-6

Ejemplares similares